Cargando…

Novel Therapies for Relapsed and Refractory Neuroblastoma

While recent increases in our understanding of the biology of neuroblastoma have allowed for more precise risk stratification and improved outcomes for many patients, children with high-risk neuroblastoma continue to suffer from frequent disease relapse, and despite recent advances in our understand...

Descripción completa

Detalles Bibliográficos
Autor principal:	Zage, Peter E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262328/ https://www.ncbi.nlm.nih.gov/pubmed/30384486 http://dx.doi.org/10.3390/children5110148

Ejemplares similares

Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
por: Zhu, Jia, et al.
Publicado: (2022)

Individualized (131)I-mIBG therapy in the management of refractory and relapsed neuroblastoma
por: George, Sally L., et al.
Publicado: (2016)

Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma
por: Saulnier Sholler, Giselle L, et al.
Publicado: (2015)

Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
por: Wieczorek, Aleksandra, et al.
Publicado: (2023)

Novel Therapies and Approaches to Relapsed/Refractory HL Beyond Chemotherapy
por: Mina, Alain Antoine, et al.
Publicado: (2019)

Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases
por: Okada, Keiko, et al.
Publicado: (2016)

Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma
por: Imaya, Masayuki, et al.
Publicado: (2022)

Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma
por: Suk, Yujin, et al.
Publicado: (2023)

The Potential Functional Roles of NME1 Histidine Kinase Activity in Neuroblastoma Pathogenesis
por: Adam, Kevin, et al.
Publicado: (2020)

Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Harris, Leonard Jeff, et al.
Publicado: (2020)

Potent in vitro and xenograft antitumor activity of a novel agent, PV-10, against relapsed and refractory neuroblastoma
por: Swift, Lucy, et al.
Publicado: (2019)

Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies
por: Chao, Mark P
Publicado: (2013)

Targeting MYCN and ALK in resistant and relapsing neuroblastoma
por: Tucker, Elizabeth R, et al.
Publicado: (2019)

Allele-specific expression reveals genes with recurrent cis-regulatory alterations in high-risk neuroblastoma
por: Sen, Arko, et al.
Publicado: (2022)

Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression
por: Woodfield, Sarah E., et al.
Publicado: (2016)

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results
por: Goldsmith, Kelly C., et al.
Publicado: (2023)

A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma
por: Saulnier Sholler, Giselle L., et al.
Publicado: (2015)

USP7 Inhibition Suppresses Neuroblastoma Growth via Induction of p53-Mediated Apoptosis and EZH2 and N-Myc Downregulation
por: Le Clorennec, Christophe, et al.
Publicado: (2023)

Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
por: Fostier, Karel, et al.
Publicado: (2012)

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
por: Su, Christopher T., et al.
Publicado: (2021)

UBE4B interacts with the ITCH E3 ubiquitin ligase to induce Ku70 and c-FLIPL polyubiquitination and enhanced neuroblastoma apoptosis
por: Le Clorennec, Christophe, et al.
Publicado: (2023)

Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings—Real-World Data
por: Wieczorek, Aleksandra, et al.
Publicado: (2023)

The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma
por: Foster, Jennifer H., et al.
Publicado: (2021)

The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma
por: Lu, Tingxun, et al.
Publicado: (2023)

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma
por: Berko, Esther R., et al.
Publicado: (2023)

Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
por: Bhatt, Parva, et al.
Publicado: (2023)

Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?
por: Thumallapally, Nishitha, et al.
Publicado: (2016)

Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma
por: Pozzi, Samantha, et al.
Publicado: (2021)

The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
por: Meier, Jeremy A., et al.
Publicado: (2022)

The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo
por: Flynn, Sean M., et al.
Publicado: (2019)

Refractory relapsing polychondritis: challenges and solutions
por: Lekpa, Fernando Kemta, et al.
Publicado: (2018)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukemia
por: Eyre, Toby A., et al.
Publicado: (2020)

Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma
por: Mora, Jaume, et al.
Publicado: (2021)

Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience
por: Olgun, Nur, et al.
Publicado: (2022)

Relapsing Polychondritis with Meningoencephalitis Refractory to Immunosuppressant Therapy
por: Al-Tabbaa, Mohammad Mousbah, et al.
Publicado: (2018)

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
por: Chim, C S, et al.
Publicado: (2018)

Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia
por: Ma, Jiale, et al.
Publicado: (2021)

Evaluating ivosidenib for the treatment of relapsed/refractory AML: design, development, and place in therapy
por: Nassereddine, Samah, et al.
Publicado: (2018)

Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy
por: Sigmund, Audrey M, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r7djl01817tbshu9j8koqfpmcp